SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 218, Issue 1, Pages -
Publisher
Rockefeller University Press
Online
2020-10-08
DOI
10.1084/jem.20201414
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial
- (2020) S.I. Ou et al. Journal of Thoracic Oncology
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Grail of RAS cancer drugs within reach
- (2020) Cormac Sheridan NATURE BIOTECHNOLOGY
- Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation
- (2020) Ankit Jambusaria et al. eLife
- The Frequency of Ras Mutations in Cancer
- (2020) Ian A. Prior et al. CANCER RESEARCH
- Allosteric inhibition of SHP2 stimulates anti-tumor immunity by transforming the immunosuppressive environment
- (2020) Elsa Quintana et al. CANCER RESEARCH
- Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma
- (2020) Nathiya Muthalagu et al. Cancer Discovery
- SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
- (2019) Tamer A. Ahmed et al. Cell Reports
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
- (2019) Wenting Liao et al. CANCER CELL
- KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
- (2019) Kevin Lou et al. Science Signaling
- Direct Ras G12C inhibitors: crossing the rubicon
- (2019) Colin R. Lindsay et al. BRITISH JOURNAL OF CANCER
- Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers
- (2019) Huai-Xiang Hao et al. MOLECULAR CANCER THERAPEUTICS
- Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition
- (2019) Meagan B. Ryan et al. CLINICAL CANCER RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- A Convergence-Based Framework for Cancer Drug Resistance
- (2018) David J. Konieczkowski et al. CANCER CELL
- CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
- (2018) Ryuma Tokunaga et al. CANCER TREATMENT REVIEWS
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
- (2018) Shuai Li et al. CLINICAL CANCER RESEARCH
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
- (2018) Gabrielle S. Wong et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
- (2018) Rasmus Hansen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
- (2018) Rasmus Hansen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
- (2018) Jhajaira M. Araujo et al. Scientific Reports
- Targeting the MAPK Pathway in RAS Mutant Cancers
- (2018) Sarah G. Hymowitz et al. Cold Spring Harbor Perspectives in Medicine
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2
- (2018) Xiaoqin Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
- (2018) Ricardo A. P. Pádua et al. Nature Communications
- Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
- (2018) Jonathan R. LaRochelle et al. Nature Communications
- The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects
- (2017) Christian W. Johnson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
- (2017) Michael Peled et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
- (2017) Jon S. Zawistowski et al. Cancer Discovery
- A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
- (2017) Grace R. Anderson et al. Cell Reports
- Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
- (2017) Leanne G. Ahronian et al. Genome Medicine
- Deconstruction of the Ras switching cycle through saturation mutagenesis
- (2017) Pradeep Bandaru et al. eLife
- Sticking It to Cancer with Molecular Glue for SHP2
- (2016) Hao Ran et al. CANCER CELL
- RAS isoforms and mutations in cancer at a glance
- (2016) G. Aaron Hobbs et al. JOURNAL OF CELL SCIENCE
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- (2016) Jorge Garcia Fortanet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- Antigen clasping by two antigen-binding sites of an exceptionally specific antibody for histone methylation
- (2016) Takamitsu Hattori et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- (2015) Luping Lin et al. NATURE GENETICS
- Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site
- (2015) Mohammad T. Mazhab-Jafari et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dragging Ras Back in the Ring
- (2014) Andrew G. Stephen et al. CANCER CELL
- Integrated RAS signaling defined by parallel NMR detection of effectors and regulators
- (2014) Matthew J Smith et al. Nature Chemical Biology
- ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays
- (2014) Camilo Guzmán et al. PLoS One
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Chemokines in Cancer
- (2014) M. T. Chow et al. Cancer Immunology Research
- Inflammatory networks and immune surveillance of pancreatic carcinoma
- (2013) Robert H Vonderheide et al. CURRENT OPINION IN IMMUNOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Emerging landscape of oncogenic signatures across human cancers
- (2013) Giovanni Ciriello et al. NATURE GENETICS
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- Endothelial Cell Heterogeneity
- (2013) W. C. Aird Cold Spring Harbor Perspectives in Medicine
- IRF-3, IRF-5, and IRF-7 Coordinately Regulate the Type I IFN Response in Myeloid Dendritic Cells Downstream of MAVS Signaling
- (2013) Helen M. Lazear et al. PLoS Pathogens
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders
- (2010) Lothar Gremer et al. HUMAN MUTATION
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Detection of Mycoplasma in cell cultures
- (2010) Lesley Young et al. Nature Protocols
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now